VIVO BIO TECH | LYNX MACH. | VIVO BIO TECH/ LYNX MACH. |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 37.4 | -20.3 | - | View Chart |
P/BV | x | 1.2 | 22.6 | 5.1% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
VIVO BIO TECH Mar-21 |
LYNX MACH. Mar-21 |
VIVO BIO TECH/ LYNX MACH. |
5-Yr Chart Click to enlarge
|
||
High | Rs | 71 | 28 | 259.6% | |
Low | Rs | 18 | 25 | 70.6% | |
Sales per share (Unadj.) | Rs | 38.6 | 0 | - | |
Earnings per share (Unadj.) | Rs | 4.2 | -7.2 | -59.1% | |
Cash flow per share (Unadj.) | Rs | 8.4 | -7.0 | -120.0% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 30.6 | 2.2 | 1,424.5% | |
Shares outstanding (eoy) | m | 13.42 | 0.60 | 2,236.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.2 | 0 | - | |
Avg P/E ratio | x | 10.5 | -3.7 | -287.6% | |
P/CF ratio (eoy) | x | 5.3 | -3.7 | -141.5% | |
Price / Book Value ratio | x | 1.5 | 12.1 | 12.0% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 597 | 16 | 3,800.3% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 86 | 1 | 8,084.9% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 518 | 0 | - | |
Other income | Rs m | 1 | 0 | 1,133.3% | |
Total revenues | Rs m | 519 | 0 | 576,411.1% | |
Gross profit | Rs m | 178 | -4 | -4,402.0% | |
Depreciation | Rs m | 56 | 0 | 55,910.0% | |
Interest | Rs m | 37 | 0 | 15,312.5% | |
Profit before tax | Rs m | 86 | -4 | -2,004.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 29 | 0 | - | |
Profit after tax | Rs m | 57 | -4 | -1,321.4% | |
Gross profit margin | % | 34.3 | 0 | - | |
Effective tax rate | % | 34.1 | 0 | - | |
Net profit margin | % | 11.0 | 0 | - |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 271 | 4 | 6,156.1% | |
Current liabilities | Rs m | 218 | 10 | 2,140.9% | |
Net working cap to sales | % | 10.1 | 0 | - | |
Current ratio | x | 1.2 | 0.4 | 287.6% | |
Inventory Days | Days | 0 | 0 | - | |
Debtors Days | Days | 51,413,598 | 0 | - | |
Net fixed assets | Rs m | 524 | 12 | 4,227.0% | |
Share capital | Rs m | 134 | 6 | 2,236.7% | |
"Free" reserves | Rs m | 277 | -5 | -5,877.1% | |
Net worth | Rs m | 411 | 1 | 31,860.5% | |
Long term debt | Rs m | 147 | 5 | 2,769.4% | |
Total assets | Rs m | 795 | 17 | 4,739.2% | |
Interest coverage | x | 3.3 | -16.9 | -19.8% | |
Debt to equity ratio | x | 0.4 | 4.1 | 8.7% | |
Sales to assets ratio | x | 0.7 | 0 | - | |
Return on assets | % | 11.8 | -24.2 | -48.7% | |
Return on equity | % | 13.8 | -333.3 | -4.1% | |
Return on capital | % | 22.1 | -61.6 | -35.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 19 | 0 | - | |
Fx outflow | Rs m | 42 | 0 | - | |
Net fx | Rs m | -23 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 142 | -5 | -3,136.3% | |
From Investments | Rs m | -228 | NA | -60,057.9% | |
From Financial Activity | Rs m | 88 | 4 | 2,179.4% | |
Net Cashflow | Rs m | 1 | 0 | -1,141.7% |
Indian Promoters | % | 42.2 | 19.2 | 220.2% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.3 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 57.8 | 80.9 | 71.5% | |
Shareholders | 12,632 | 2,547 | 496.0% | ||
Pledged promoter(s) holding | % | 0.0 | 9.6 | - |
Compare VIVO BIO TECH With: VA TECH WABAG SIS SUN PHARMA ADV. RES. DELTA CORP BLS INTERNATIONAL SERVICES
On Tuesday, Indian share markets ended on a firm note as fag-end buying in Reliance Industries and other index heavyweight stocks pushed benchmark indices higher.